Pharma Focus Asia

Teva and Jiangsu Nhwa Establish Strategic Collaboration to Enhance Patient Access to AUSTEDO® in China

Monday, February 26, 2024

Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has partnered with Jiangsu Nhwa Pharmaceutical Co., Ltd (“Nhwa”) to market and distribute AUSTEDO (deutetrabenazine) in China. This collaboration aims to improve patient access to AUSTEDO, which is used to treat neurodegenerative and movement disorders such as chorea associated with Huntington’s disease (HD) and tardive dyskinesia (TD) in adults. Nhwa's expertise in China's neuro-psychiatric health sector will be leveraged to advance healthcare in the region.

"The collaboration with Nhwa is crucial as they bring deep neuro-psychiatry expertise, spanning from research and development to commercialization," stated Theodor Wee, General Manager of Teva Greater China. "Together, we aim to facilitate the efficient delivery of safe, high-quality medications, contributing to the resilience of China's healthcare system."

Huntington’s disease, a rare and fatal neurodegenerative disorder, often presents with chorea, involuntary muscle movements. Tardive dyskinesia, another disorder causing uncontrollable movements, particularly affects individuals on long-term antipsychotic medication.

"AUSTEDO, the first deuterated drug approved in China, introduces an innovative therapeutic approach for chorea associated with Huntington’s disease and tardive dyskinesia," noted Sun Jiaquan, President and CEO of Nhwa. "These debilitating conditions significantly impair daily functioning and quality of life."

AUSTEDO's deuterium technology, replacing hydrogen atoms with deuterium, potentially leads to lower metabolism rates, enabling less frequent dosing for patients.

"Our commitment extends to addressing the urgent needs of patients in China through innovative medications," affirmed Mark Sabag, EVP and Head of International Markets at Teva. "This partnership not only strengthens AUSTEDO's global standing but also aligns with Teva's broader mission of fostering better health outcomes worldwide."

AUSTEDO stands as the inaugural vesicular monoamine transporter 2 (VMAT2) inhibitor sanctioned by the U.S. Food and Drug Administration for treating tardive dyskinesia (TD) in adults and chorea associated with Huntington’s disease (HD).

 

Source: tevapharm.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024